bluebird bio Inc
NASDAQ:BLUE

Watchlist Manager
bluebird bio Inc Logo
bluebird bio Inc
NASDAQ:BLUE
Watchlist
Price: 4.97 USD
Market Cap: 48.7m USD

bluebird bio Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

bluebird bio Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
bluebird bio Inc
NASDAQ:BLUE
Income from Continuing Operations
-$200m
CAGR 3-Years
29%
CAGR 5-Years
20%
CAGR 10-Years
-12%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$2.4B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$8.1B
CAGR 3-Years
35%
CAGR 5-Years
46%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

bluebird bio Inc
Glance View

Market Cap
48.7m USD
Industry
Biotechnology

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.

BLUE Intrinsic Value
Not Available

See Also

What is bluebird bio Inc's Income from Continuing Operations?
Income from Continuing Operations
-200m USD

Based on the financial report for Mar 31, 2025, bluebird bio Inc's Income from Continuing Operations amounts to -200m USD.

What is bluebird bio Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-12%

Over the last year, the Income from Continuing Operations growth was 34%. The average annual Income from Continuing Operations growth rates for bluebird bio Inc have been 29% over the past three years , 20% over the past five years , and -12% over the past ten years .

Back to Top